The Committee on Energy and Commerce is the oldest standing legislative committee (established 1795) in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee. The Energy and Commerce Committee is at the forefront of all issues and policies powering America’s economy, including our global competitive edge in energy, technology, and health care. The committee is led by E&C Chairman Brett Guthrie (KY-02) and E&C Ranking Member Frank Pallone (NJ-06). The Subcommittee on Health is led by Chairman Morgan Griffith (VA-09) and Ranking Member Diana DeGette (C)-01).
Today's legislative hearing is necessary to continue essential programs that are vital to
our health care infrastructure. Many of the bills before us expire at the end of this fiscal year
and must be reauthorized. One of the bills that will be discussed today is H.R. 4273,
the Over-the-County Monograph Drug User Fee Amendments, led by Mr. Latta and Ranking Member
DeGette. The Coronavirus Aid, Relief and Economic Security Cares Act, which passed in 2020,
modernized the regulation of over-the-counter monograph drugs and products. It also created
a new user fee program to support this new framework, also known as OMUFA, or colloquially
OMUFA. And I hope I pronounced the colloquialism right, but it's another one of those
fees that we have that make things important, make important things happen. Generally,
a company can market an over-the-counter drug if they either submit a new drug application
or go through the over-the-counter monograph process. Prior to 2020, that involved a lengthy,
burdensome three-phase rulemaking process. This led to Congress creating a new regulatory
framework that allows FDA to issue administrative orders, determining a product is generally
recognized as safe and effective or grace, and simultaneously establishing a new user fee
program to help ensure this process is effective and is streamlined. This is the first reauthorization
of OMUFA. We hope to work in a bipartisan way to address any outstanding issues to ensure
this program is functioning how Congress initially intended, including minimizing regulatory burdens,
supporting innovation, and increasing access to products in a safe and efficient manner.
We will also consider other legislation that will help encourage the FDA to be more flexible
in their review process. H.R. 3686, the Safe Sunscreen Standards Act, left by Dr. Joyce and
Ms. Dingell, would require the FDA to consider the use of certain real-world evidence-based and
non-animal testing methods when it comes to evaluating new sunscreen active ingredients
in the United States. We are behind other countries in bringing innovative sunscreens to the market,
and this bill will help to bridge the gap. During our last hearing on OMUFA, we had a
discussion about the need for more innovative sunscreens to be available in the United States,
and I look forward to the discussion around these policies today.
Along similar lines, the FDA must keep pace with current technological advancements,
which includes greater utilization of non-animal testing methods. H.R. 2821,
led by Representatives Carter and Barragan, would help support FDA's efforts to do just that.
Congress gave the FDA the ability in 2022 when FDA Modernization 2.0 was signed into law,
but the FDA has failed to fully implement these practices. This legislation would require the
FDA to finally update its regulations to account for non-animal testing. This bill does not require
non-animal testing. It simply provides an option if companies wish to pursue less costly methods,
such as computer AI modeling or organ chip testing. There are also two important
reauthorizations in front of us today that serve a vital role in helping our medical workforce,
which are the Title VII and Title VIII reauthorizations. These programs allocate
resources for scholarships and educational assistance so students from underserved
backgrounds who are often from rural areas can pursue medical careers and help support
the medical workforce that Americans widely rely upon. It is crucial for Congress to take a close
look at these programs to ensure resources are going to areas and patients who need it most.
We are also discussing legislation that will continue grants for certain health care services
in rural areas to help to increase the use of telehealth so patients can access care more
easily. Reauthorizing the Telehealth Resource Center's grant program will support our telehealth
infrastructure that has become a lifeline for both providers and patients across the country,
especially in rural areas. Considering each of these reauthorizations is an important step
forward to ensure the program is working as intended. I look forward to hearing from our
witnesses today regarding the importance of these programs and to ensure that they are reauthorized
in a timely manner. That said, I would also say that the Health Subcommittee has great advantages
in many ways. One of those being is that when somebody is sick or needs health care,
they don't look at what party they identify with or what their philosophical background is.
This Subcommittee has a long history and I hope to be a part of continuing
that long history of doing bipartisan work for the betterment of the American people and the
American patients. And I know that my colleague, the Ranking Member, Ms. DeGette, feels the same
way. We have worked on issues over the years that I've been in Congress and I appreciate
the opportunity to work with you as a Ranking Member. And I now recognize Ms. DeGette for her
five-minute opening remarks.